Epidemiology


  • Most common in females 20–50 years old.

Etiology


Pathophysiology


Central pain processing dysfunction (central sensitization / neuroendocrine dysregulation; abnormal pain amplification).

Clinical features


  • Chronic Widespread Pain:
    • Present for ≥ 3 months.
    • Involves both sides of the body, above and below the waist, and axial skeleton.
    • Characterized by hyperalgesia (exaggerated pain response) and allodynia (pain from non-painful stimuli). c
  • Systemic Symptoms:
    • Fatigue & non-restorative sleep (“waking unrefreshed”). c
    • Cognitive disturbance (“fibro fog”: impaired memory, poor concentration).
    • Paresthesias, mood disturbances, and morning stiffness.
  • Physical Exam (PE):
    • Point tenderness at multiple soft tissue sites (e.g., trapezius, lateral epicondyle, medial knee).
    • Normal joint examination (no synovitis, joint effusion, erythema, warmth, or structural deformities).
    • Normal objective neurological exam (normal muscle strength, deep tendon reflexes, and sensation).

Diagnostics


  • Initial/Screening: Clinical diagnosis based on ACR Criteria (Widespread Pain Index [WPI] ≥ 7 + Symptom Severity [SS] score ≥ 5 OR WPI 3–6 + SS ≥ 9; symptoms persisting for ≥ 3 months without another explanatory disorder).
  • Key Labs (to exclude secondary causes):
    • CBC, BMP: Normal.
    • Inflammatory markers: ESR and CRP are normal (crucial negative finding). c
    • TSH: Normal (rules out hypothyroidism).
    • Creatine Kinase (CK): Normal (rules out inflammatory/statin-induced myopathy).
  • Confirmatory/Gold Standard: None (clinical diagnosis of exclusion).
  • Autoantibodies: ANA, RF, anti-CCP are not routinely indicated unless specific signs of connective tissue disease are present (reduces false positives).
  • Imaging/Biopsy: Not indicated; radiographically and histologically normal.

Differential Diagnostics

  • Polymyalgia Rheumatica (PMR):
    • Diff by age > 50 yo, morning stiffness localized to shoulder/hip girdle, markedly elevated ESR/CRP (> 40–50 mm/hr), and dramatic response to low-dose systemic corticosteroids.
  • Hypothyroidism:
    • Diff by elevated TSH, weight gain, delayed DTR relaxation phase, cold intolerance, and possible mild ↑ CK.
  • Polymyositis / Dermatomyositis:
    • Diff by objective proximal muscle weakness (difficulty climbing stairs, combing hair), elevated CK/aldolase, abnormal EMG, and positive muscle biopsy.
  • Rheumatoid Arthritis (RA):
    • Diff by symmetric peripheral inflammatory arthritis (MCP, PIP, MTP), joint swelling/synovitis, elevated ESR/CRP, and (+) RF / anti-CCP antibodies.
  • Systemic Lupus Erythematosus (SLE):
    • Diff by systemic features (malar rash, photosensitivity, oral ulcers, serositis, nephritis, cytopenias), (+) ANA, and (+) anti-dsDNA/anti-Smith.

Treatment


  1. First-line (Non-Pharmacologic - Preferred):
    • Regular low-impact aerobic exercise (walking, swimming).
    • CBT and sleep hygiene education.
  2. Second-line (Pharmacotherapy):
    • SNRIs: Duloxetine, Milnacipran (preferred if comorbid depression/neuropathic pain).
    • TCAs: Amitriptyline (improves sleep and central pain).
    • Gabapentinoids: Pregabalin (preferred if prominent sleep disruption).
  3. Refractory:
    • Combination pharmacotherapy (e.g., SNRI + Pregabalin); pain rehabilitation.
  4. Ineffective / Contraindicated (High-Yield USMLE Trap):
    • Avoid Opioids, Systemic Steroids, and NSAIDs (ineffective for central pain; high risk of adverse effects).